Tyrosine for Methamphetamine Dependence - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000322

Purpose

The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."

Condition	Intervention	Phase
Amphetamine-Related Disorders	Behavioral: Tyrosine	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control
Official Title:	Tyrosine for Methamphetamine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine

Drug Information available for: Methamphetamine hydrochloride Tyrosine Amphetamine Methamphetamine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Craving
Drug use
Retention
Functioning

Estimated Enrollment:	89
Study Start Date:	April 1997
Estimated Study Completion Date:	December 2001

Detailed Description:

Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment and craving.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.

Exclusion Criteria:

No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000322

Locations

United States, California
Haight Ashbury Free Clinics
San Francisco, California, United States, 94117

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Gantt Galloway, Pharm.D.

Haight Ashbury Free Clinics

More Information

No publications provided

Study ID Numbers:	NIDA-10739-1, R01-10739-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000322 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Dopamine Uptake Inhibitors
Neurotransmitter Agents
Adrenergic Agents
Tyrosine
Disorders of Environmental Origin
Central Nervous System Stimulants
Methamphetamine

Dopamine
Amphetamine-Related Disorders
Mental Disorders
Substance-Related Disorders
Amphetamine
Dopamine Agents
Peripheral Nervous System Agents

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Sympathomimetics
Physiological Effects of Drugs
Disorders of Environmental Origin
Central Nervous System Stimulants
Pharmacologic Actions

Methamphetamine
Amphetamine-Related Disorders
Mental Disorders
Autonomic Agents
Therapeutic Uses
Substance-Related Disorders
Amphetamine
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009